A detailed history of Black Rock Inc. transactions in Altimmune, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 5,321,089 shares of ALT stock, worth $43.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,321,089
Previous 4,042,226 31.64%
Holding current value
$43.9 Million
Previous $41.1 Million 14.01%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$5.91 - $10.23 $7.56 Million - $13.1 Million
1,278,863 Added 31.64%
5,321,089 $35.4 Million
Q1 2024

May 10, 2024

SELL
$8.22 - $13.81 $20,393 - $34,262
-2,481 Reduced 0.06%
4,042,226 $41.1 Million
Q4 2023

Feb 13, 2024

BUY
$2.14 - $11.62 $551,672 - $3 Million
257,791 Added 6.81%
4,044,707 $45.5 Million
Q3 2023

Nov 13, 2023

BUY
$2.4 - $3.45 $294,340 - $423,114
122,642 Added 3.35%
3,786,916 $9.85 Million
Q2 2023

Aug 11, 2023

BUY
$3.45 - $5.97 $7.83 Million - $13.6 Million
2,270,219 Added 162.85%
3,664,274 $12.9 Million
Q1 2023

May 12, 2023

BUY
$4.19 - $16.83 $167,692 - $673,570
40,022 Added 2.96%
1,394,055 $5.88 Million
Q4 2022

Feb 13, 2023

BUY
$8.74 - $16.45 $1.18 Million - $2.22 Million
134,733 Added 11.05%
1,354,033 $22.3 Million
Q3 2022

Nov 14, 2022

BUY
$10.67 - $22.41 $2.74 Million - $5.76 Million
257,116 Added 26.72%
1,219,300 $15.6 Million
Q2 2022

Aug 12, 2022

SELL
$3.94 - $11.77 $7.78 Million - $23.2 Million
-1,974,140 Reduced 67.23%
962,184 $11.3 Million
Q1 2022

May 12, 2022

SELL
$5.9 - $9.45 $117,663 - $188,461
-19,943 Reduced 0.67%
2,936,324 $17.9 Million
Q4 2021

Feb 10, 2022

BUY
$8.69 - $12.48 $125,805 - $180,672
14,477 Added 0.49%
2,956,267 $27.1 Million
Q3 2021

Nov 09, 2021

BUY
$8.43 - $16.81 $3.24 Million - $6.46 Million
384,548 Added 15.04%
2,941,790 $33.3 Million
Q2 2021

Aug 11, 2021

BUY
$9.85 - $16.46 $25.2 Million - $42.1 Million
2,557,242 New
2,557,242 $25.2 Million

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $404M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.